IRIS  Catalogo Istituzionale della Ricerca dell'Università degli Studi del Molise

RINALDI, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.449
EU - Europa 6.997
AS - Asia 3.250
SA - Sud America 1.039
AF - Africa 486
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 19.231
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.187
RU - Federazione Russa 5.476
SG - Singapore 1.524
BR - Brasile 799
CN - Cina 487
FR - Francia 368
CI - Costa d'Avorio 339
VN - Vietnam 317
IT - Italia 307
DE - Germania 275
HK - Hong Kong 190
BD - Bangladesh 187
IN - India 141
CA - Canada 132
GB - Regno Unito 132
AR - Argentina 88
MX - Messico 70
PL - Polonia 70
NL - Olanda 67
IQ - Iraq 58
ZA - Sudafrica 55
TR - Turchia 45
JP - Giappone 40
ES - Italia 36
ID - Indonesia 36
AT - Austria 34
PK - Pakistan 34
CZ - Repubblica Ceca 32
LT - Lituania 32
EC - Ecuador 30
IE - Irlanda 29
CO - Colombia 28
FI - Finlandia 28
SA - Arabia Saudita 27
UA - Ucraina 27
MA - Marocco 26
SE - Svezia 26
VE - Venezuela 25
EG - Egitto 19
PH - Filippine 19
UZ - Uzbekistan 19
CL - Cile 17
AE - Emirati Arabi Uniti 16
MY - Malesia 16
PY - Paraguay 14
UY - Uruguay 13
NP - Nepal 12
PE - Perù 12
JM - Giamaica 11
TH - Thailandia 11
BO - Bolivia 10
HN - Honduras 10
BE - Belgio 9
JO - Giordania 9
AU - Australia 7
CR - Costa Rica 7
DZ - Algeria 7
RO - Romania 7
TN - Tunisia 7
AZ - Azerbaigian 6
ET - Etiopia 6
KE - Kenya 6
KZ - Kazakistan 6
OM - Oman 6
AM - Armenia 5
BB - Barbados 5
BG - Bulgaria 5
BY - Bielorussia 5
CH - Svizzera 5
IL - Israele 5
KR - Corea 5
KW - Kuwait 5
PA - Panama 5
PR - Porto Rico 5
PT - Portogallo 5
SN - Senegal 5
GT - Guatemala 4
NI - Nicaragua 4
DO - Repubblica Dominicana 3
GA - Gabon 3
HR - Croazia 3
HU - Ungheria 3
LV - Lettonia 3
LY - Libia 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BZ - Belize 2
CG - Congo 2
EE - Estonia 2
GY - Guiana 2
IR - Iran 2
LB - Libano 2
LU - Lussemburgo 2
MN - Mongolia 2
Totale 19.207
Salva come PNG Salva come JPEG
Città #
Dallas 2.646
Moscow 1.821
San Jose 1.704
Ashburn 691
Singapore 616
The Dalles 370
Abidjan 339
Lauterbourg 252
New York 192
Hong Kong 183
Frankfurt am Main 177
Beijing 172
Los Angeles 133
Ho Chi Minh City 120
São Paulo 82
Santa Clara 80
Warsaw 59
Hanoi 57
Chennai 54
Amsterdam 50
Orem 48
Boardman 47
Brooklyn 46
Denver 44
Nuremberg 43
Montreal 42
Tokyo 39
London 37
Toronto 37
Chicago 34
Assago 30
Boston 30
Munich 30
Johannesburg 28
Dublin 27
Phoenix 27
San Francisco 27
Brno 26
Stockholm 26
Rio de Janeiro 24
Atlanta 23
Hillsboro 23
Baghdad 22
Mumbai 21
Council Bluffs 20
Mexico City 20
Naples 19
Lahore 18
Milan 18
Poplar 18
Rome 18
Tashkent 18
Belo Horizonte 17
Da Nang 17
Manchester 17
Ankara 16
Brasília 15
Columbus 15
Haiphong 15
Houston 15
West Jordan 14
Guarulhos 13
Querétaro 13
Campobasso 12
Curitiba 12
Helsinki 12
Montevideo 12
Ottawa 12
Charlotte 11
Jakarta 11
New Delhi 11
Seattle 11
Volta Redonda 11
Buffalo 10
Cape Town 10
Caracas 10
Dhaka 10
Falkenstein 10
Goiânia 10
Jeddah 10
Medellín 10
Quito 10
Brussels 9
Casablanca 9
Córdoba 9
Erbil 9
Guayaquil 9
Vienna 9
Ha Long 8
Kingston 8
Lappeenranta 8
Ribeirão Preto 8
Riyadh 8
Roubaix 8
Santiago 8
Santo André 8
São Bernardo do Campo 8
Terzigno 8
Amman 7
Kuala Lumpur 7
Totale 11.248
Salva come PNG Salva come JPEG
Nome #
Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study 618
Metabolic Rewiring of Bacterial Pathogens in Response to Antibiotic Pressure—A Molecular Perspective 539
Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study 166
Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study 146
A genic and epigenetic combination therapy for liver cancer 140
Advances in the Insulin–Heart Axis: Current Therapies and Future Directions 138
A suspected infective endocarditis in patients with a history of chronic HCV infection 129
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors 128
Advances in Pharmacological Approaches for Managing Hypercholesterolemia: A Comprehensive Overview of Novel Treatments 128
Adherence to AISF recommendations for integrated management of hepatocellular carcinoma in a real–world clinical practice 127
Angiogenesis inhibitors for the treatment of hepatocellular carcinoma 126
Advances in Nanomedicine for Precision Insulin Delivery 126
[Inhibitors of intra-cystic secretion: novel therapies in ADPKD (Autosomal Dominant Polycystic Kidney Disease)] 125
A gene and epigenetic combination therapy for liver cancer treatment 124
Diabetic Gastroparesis: Navigating Pathophysiology and Nutritional Interventions 121
. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics 120
Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes 120
Lenvatinib Is Highly Effective in Patients with Hepatocellular Carcinoma Related to Both Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Etiology: A Propensity Score Analysis 120
Ruolo patogenetico dell'adiponectina nella steatosi associata ad epatite C 118
Impact of Acute Kidney Injury on the COVID-19 In-Hospital Mortality in Octogenarian Patients: Insights from the COVOCA Study 118
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study 116
The impact of new onset diabetes on cardiovascular risks in orthotopic liver transplant recipients: findings from the COLT study 116
[Next Generation Sequencing and ADPKD] 116
A Controversial Case of a Double Hepatic Incidentaloma in a Male Patient with Kidney Failure 116
Alcohol Consumption and Liver Metabolism in the Era of MASLD: Integrating Nutritional and Pathophysiological Insights 116
Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease 114
Cardiac Hypertrophy: from Pathophysiological Mechanisms to Heart Failure Development 113
Current Knowledge on the Pathophysiology of Lean/Normal-Weight Type 2 Diabetes 112
Antibiotic use and associated factors in a large sample of hospitalised older people 112
An atypical resentation of a parasitic infection, simulating abdominal expansive mass: a multidisciplinary case report 110
Oxidative Stress and Cardiovascular Complications in Type 2 Diabetes: From Pathophysiology to Lifestyle Modifications 110
Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications 110
A clear case of portal hypertension: a logical consequence of liver cirrhosis? 108
An atypical presentation of a rare parasitic infection of Fasciola hepatica: a multidisciplinary case report. 108
Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options 107
Adherence to Barcelona Clinic Liver Cancer guidelines in field-practice: results of Progetto Epatocarcinoma Campania 106
Association between Renal Function at Admission and COVID-19 in-Hospital Mortality in Southern Italy: Findings from the Prospective Multicenter Italian COVOCA Study 103
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management 102
Application and internal validation of lung ultrasound score in COVID-19 setting: The ECOVITA observational study 100
Predictive Value of Fatty Liver Index for Long-Term Cardiovascular Events in Patients Receiving Liver Transplantation: The COLT Study 100
Effects of metformin in heart failure: From pathophysiological rationale to clinical evidence 98
Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations 98
CURRENT HEPATOCELLULAR CARCINOMA SYSTEMIC PHARMACOLOGICAL TREATMENT OPTIONS 97
Insulin–Heart Axis: Bridging Physiology to Insulin Resistance 93
Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: A multicenter observational study 92
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care 87
Cardiovascular benefits from gliflozins: Effects on endothelial function 85
The Dual Burden: Exploring Cardiovascular Complications in Chronic Kidney Disease 85
Neurophysiological assessment of peripheral neuropathy through whole plantar nerve conduction in type 2 diabetes mellitus and healthy control subjects 84
HCV-related steatosis and risk of atherosclerosis 80
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives 79
Steatosis is a determinant of fibrosis progression in chronic hepatitis C and is correlated both with body composition and viral factors 78
Drug–drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients 78
Hepatocellular carcinoma and non alcoholic fatty liver disease; a dangerous liaison 78
What changed in the Italian internal medicine and geriatric wards during the lockdown 77
Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations 77
Liver fibrosis by FibroScan is highly prevalent in type 2 diabetic patients with NAFLD and fairly normal liver enzymes but increased uric acid 73
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry 72
The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial 72
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19 72
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives 71
Sex-difference of multifactorial intervention on cardiovascular and mortality risk in DKD: post-hoc analysis of a randomised clinical trial 70
Late Hepatocellular Carcinoma Occurrence in Patients Achieving Sustained Virological Response After Direct-Acting Antiviral Therapy: A Matter of Follow-Up or Something Else? 70
Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma 70
Features of microvessel density (MVD) and angiogenesis inhibitors in therapeutic approach of hepatocellular carcinoma (HCC) 70
Multidrug-Resistant Infections and Metabolic Syndrome: An Overlooked Bidirectional Relationship 70
Epigenetic and Genetic Keys to Fight HPV-Related Cancers 69
Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register) 69
Cryptogenic cirrhosis is associated with cardiometabolic and oncologic comorbidities and poor liver-related prognosis 69
Sonoporation by microbubbles as gene therapy approach for liver cancer 69
The importance of the thick ascending limb of Henle's loop in renal physiology and pathophysiology 68
Late HCC onset after direct antiviral agents therapy in patients with sustained virological response: do we need to reconsider their efficacy according to long term follow-up? 66
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects 66
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 65
Early changes of liver stiffness in HCV patients undergoing treatment with direct-acting antivirals (DDAs): a multicenter study 65
Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies 65
Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study 64
Impact of empagliflozin as add-on to metformin vs metformin continuation on MASLD progression in type 2 diabetes: The IMAGIN Study 64
Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis/compensated cirrhosis 64
Influence of antiviral therapy on liver stiffness evaluation in chronic hepatitis HBV patients in a real world setting: preliminary data in a multicentric study 63
HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis 63
Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy 63
IMPACT OF TYPE II DIABETES ON HCC APPEARANCE IN PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 63
Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era? 63
Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study 63
Role of tight glycemic control during acute coronary syndrome on CV outcome in type 2 diabetes 62
Insulin resistance and cancer: molecular links and clinical perspectives 62
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study 62
Mortality rate and risk factors for gastrointestinal bleeding in elderly patients 61
Peripheral Neuropathy in Diabetes Mellitus: Pathogenetic Mechanisms and Diagnostic Options 61
NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes 61
Nonalcoholic fatty liver disease: Evolving paradigms 61
Twelve-week course of pIFN-a-2a/ribavirin is an optimized regimen for treatment of HCV genotype 2 but not genotype 3 non-cirrhotic patients with RVR 61
HCC recurrence after DAA treatment in HCV patients 61
HCV-related steatosis and risk of atherosclerosis 61
Lactate in pleural and abdominal effusions 60
Metformin: An old drug against old age and associated morbidities 60
Characteristics and outcome of cryptogenic cirrhosis in Italy 60
Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis 60
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 60
Totale 9.902
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.538
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.538
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024334 0 0 0 0 2 151 11 44 5 17 20 84
2024/20253.369 520 223 254 23 416 66 112 121 453 74 490 617
2025/202615.447 530 1.404 1.774 735 3.353 3.104 1.682 639 508 1.157 419 142
2026/2027132 132 0 0 0 0 0 0 0 0 0 0 0
Totale 19.282